Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 159

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition

Open access
Weigert, Oliver, Lane, Andrew A., Bird, Liat, Kopp, Nadja, Chapuy, Bjoern, van Bodegom, Diederik, Toms, Angela V., Marubayashi, Sachie, Christie, Amanda L., McKeown, Michael, Paranal, Ronald M., Bradner, James E., Yoda, Akinori, Gaul, Christoph, Vangrevelinghe, Eric, Romanet, Vincent, Murakami, Masato, Tiedt, Ralph, Ebel, Nicolas, Evrot, Emeline, De Pover, Alain, Régnier, Catherine H., Erdmann, Dirk, Hofmann, Francesco, Eck, Michael J., Sallan, Stephen E., Levine, Ross L., Kung, Andrew L., Baffert, Fabienne, Radimerski, Thomas, Weinstock, David M.·2012·Journal of Experimental Medicine

Abstract

Enzymatic inhibitors of Janus kinase 2 (JAK2) are in clinical development for the treatment of myeloproliferative neoplasms (MPNs), B cell acute lymphoblastic leukemia (B-ALL) with rearrangements of the cytokine receptor subunit cytokine receptor–like factor 2 (CRLF2), and other tumors with constitutive JAK2 signaling. In this study, we identify G935R, Y931C, and E864K mutations within the JAK2 kinase domain that confer resistance across a panel of JAK inhibitors, whether present in cis with JAK2 V617F (observed in MPNs) or JAK2 R683G (observed in B-ALL). G935R, Y931C, and E864K do not reduce the sensitivity of JAK2-dependent cells to inhibitors of heat shock protein 90 (HSP90), which promote the degradation of both wild-type and mutant JAK2. HSP90 inhibitors were 100–1,000-fold more potent against CRLF2-rearranged B-ALL cells, which correlated with JAK2 degradation and more extensive blockade of JAK2/STAT5, MAP kinase, and AKT signaling. In addition, the HSP90 inhibitor AUY922 prolonged survival of mice xenografted with primary human CRLF2-rearranged B-ALL further than an enzymatic JAK2 inhibitor. Thus, HSP90 is a promising therapeutic target in JAK2-driven cancers, including those with genetic resistance to JAK enzymatic inhibitors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20111694

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 159

Metadata

Authors
Weigert, O., Lane, A. A., Bird, L., Kopp, N., Chapuy, B., van Bodegom, D., Toms, A. V., Marubayashi, S., Christie, A. L., McKeown, M., Paranal, R. M., Bradner, J. E., Yoda, A., Gaul, C., Vangrevelinghe, E., Romanet, V., Murakami, M., Tiedt, R., Ebel, N., Evrot, E., De Pover, A., Régnier, C. H., Erdmann, D., Hofmann, F., Eck, M. J., Sallan, S. E., Levine, R. L., Kung, A. L., Baffert, F., Radimerski, T., & Weinstock, D. M.
Venue
Journal of Experimental Medicine
Published
2012-01-23
Volume
209
Issue
2
Pages
259-273
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W2154564841
Cited by
159
References
2
FWCI
11.10
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. https://app.cochat.ai/papers/10.1084/jem.20111694
The paper
Weigert, O., Lane, A. A., Bird, L., Kopp, N., Chapuy, B., van Bodegom, D., Toms, A. V., Marubayashi, S., Christie, A. L., McKeown, M., Paranal, R. M., Bradner, J. E., Yoda, A., Gaul, C., Vangrevelinghe, E., Romanet, V., Murakami, M., Tiedt, R., Ebel, N., . . . Weinstock, D. M. (2012). Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20111694

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.